DEF 14C - http://archive.fast-edgar.com//20161031/AA2ZW22CZC2RP2SD222A2WX29VWNZZ22ZV82/ The companies anticipate that the combined business (incorporating Inovenn and Lifesciencehub) should create potential operating synergies, lower diversified risk, existing sales of products/services, “cross-franchise” opportunities to incorporate patented technologies into new products, access to a wider range of core skills (including marketing, development and formulation), critical mass for the purpose and enhanced access to capital and a greater chance to apply for listing on the London Stock Exchange’s international market for smaller growing companies (AIM) to provide all shareholders liquidity.